JP2017525734A - 癌の治療において有用なイソキノリノン誘導体 - Google Patents
癌の治療において有用なイソキノリノン誘導体 Download PDFInfo
- Publication number
- JP2017525734A JP2017525734A JP2017512003A JP2017512003A JP2017525734A JP 2017525734 A JP2017525734 A JP 2017525734A JP 2017512003 A JP2017512003 A JP 2017512003A JP 2017512003 A JP2017512003 A JP 2017512003A JP 2017525734 A JP2017525734 A JP 2017525734A
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- halo
- nitro
- alkoxy
- added
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 **c(c(*)c1*)c(*)c(*)c1N Chemical compound **c(c(*)c1*)c(*)c(*)c1N 0.000 description 7
- PWVRVIMIXYJITM-LUCVSDRKSA-N CC(C)(C)OC(N/C(/N/C=C\C=N)=N\C(OC(C)(C)C)=O)=O Chemical compound CC(C)(C)OC(N/C(/N/C=C\C=N)=N\C(OC(C)(C)C)=O)=O PWVRVIMIXYJITM-LUCVSDRKSA-N 0.000 description 1
- DAAYSOZYQUIPIE-UHFFFAOYSA-N CN(C(C=O)=C(c1c2cccc1)Br)C2=O Chemical compound CN(C(C=O)=C(c1c2cccc1)Br)C2=O DAAYSOZYQUIPIE-UHFFFAOYSA-N 0.000 description 1
- RKCMIDKGQQNHRS-UHFFFAOYSA-N CN(C(CO)=Cc(cc1)c2cc1[N+]([O-])=O)C2=O Chemical compound CN(C(CO)=Cc(cc1)c2cc1[N+]([O-])=O)C2=O RKCMIDKGQQNHRS-UHFFFAOYSA-N 0.000 description 1
- URICGLRJUOQKEQ-UHFFFAOYSA-N CN(c1c(-c(cc2)c3cc2[N+]([O-])=O)nc(Nc2cc(OC)cc(N)c2)nc1)C3=O Chemical compound CN(c1c(-c(cc2)c3cc2[N+]([O-])=O)nc(Nc2cc(OC)cc(N)c2)nc1)C3=O URICGLRJUOQKEQ-UHFFFAOYSA-N 0.000 description 1
- DESOTFYFJDLLOP-UHFFFAOYSA-N COc(c([N+]([O-])=O)c1)cc(C=C(CO)O2)c1C2=O Chemical compound COc(c([N+]([O-])=O)c1)cc(C=C(CO)O2)c1C2=O DESOTFYFJDLLOP-UHFFFAOYSA-N 0.000 description 1
- LSPNCJLDZUVKGN-UHFFFAOYSA-N COc(cc(cc1)OCCN2CCCC2)c1NC(N)=N Chemical compound COc(cc(cc1)OCCN2CCCC2)c1NC(N)=N LSPNCJLDZUVKGN-UHFFFAOYSA-N 0.000 description 1
- WSKXSFRQQBHKRR-UHFFFAOYSA-N COc1cc(NC(N)=N)cc(N)c1 Chemical compound COc1cc(NC(N)=N)cc(N)c1 WSKXSFRQQBHKRR-UHFFFAOYSA-N 0.000 description 1
- BTDGLZSKNFJBER-UHFFFAOYSA-N NC(Nc(cc1)ccc1C#N)=N Chemical compound NC(Nc(cc1)ccc1C#N)=N BTDGLZSKNFJBER-UHFFFAOYSA-N 0.000 description 1
- GRSCIMXGMTUWQD-UHFFFAOYSA-N NC(Nc1cc(C#N)ccc1)=N Chemical compound NC(Nc1cc(C#N)ccc1)=N GRSCIMXGMTUWQD-UHFFFAOYSA-N 0.000 description 1
- ANSLAPNHXOSLGV-UHFFFAOYSA-N Nc1cc(Nc(nc2-c(cc3)c4cc3N)ncc2NC4=O)ccc1 Chemical compound Nc1cc(Nc(nc2-c(cc3)c4cc3N)ncc2NC4=O)ccc1 ANSLAPNHXOSLGV-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14306352 | 2014-09-02 | ||
| EP14306352.7 | 2014-09-02 | ||
| PCT/EP2015/070082 WO2016034642A1 (en) | 2014-09-02 | 2015-09-02 | Isoquinolinone derivatives useful in the treatment of cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017525734A true JP2017525734A (ja) | 2017-09-07 |
| JP2017525734A5 JP2017525734A5 (enExample) | 2018-10-11 |
Family
ID=51494243
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017512003A Pending JP2017525734A (ja) | 2014-09-02 | 2015-09-02 | 癌の治療において有用なイソキノリノン誘導体 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US9944641B2 (enExample) |
| EP (1) | EP3189051A1 (enExample) |
| JP (1) | JP2017525734A (enExample) |
| CN (1) | CN106795154B (enExample) |
| BR (1) | BR112017003651A2 (enExample) |
| MX (1) | MX2017002544A (enExample) |
| RU (1) | RU2690853C2 (enExample) |
| WO (1) | WO2016034642A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3481826T3 (da) * | 2016-07-08 | 2022-01-10 | Rigel Pharmaceuticals Inc | Tyrosinkinaseinhibitorer |
| CN106699608A (zh) * | 2016-12-26 | 2017-05-24 | 常州大学 | 一种含有强吸电子基团的苯胍及其盐的制备方法 |
| CN111683976B (zh) | 2018-02-05 | 2022-11-18 | 生物辐射实验室股份有限公司 | 具有阴离子交换-疏水混合模式配体的色谱树脂 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009112524A1 (en) * | 2008-03-12 | 2009-09-17 | 4Sc Ag | Pyridopyrimidines as plk1 ( polo-like kinase) inhibitors |
| JP2015504081A (ja) * | 2012-01-23 | 2015-02-05 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｉｇｆ−１ｒ／ｉｒ阻害剤としての５，８−ジヒドロ−６ｈ−ピラゾロ［３，４−ｈ］キナゾリン |
| JP2016515537A (ja) * | 2013-03-15 | 2016-05-30 | ダナ ファーバー キャンサー インスティテュート，インコーポレイテッド | ピリミド−ジアゼピノン化合物および障害の治療方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO2783B1 (en) * | 2005-09-30 | 2014-03-15 | نوفارتيس ايه جي | Compounds 2-Amino-7, 8-dihydro-6H-Bayredo (3,4-D) Pyrimidine-5-Ones |
| US9029391B2 (en) | 2011-01-24 | 2015-05-12 | Viiv Healthcare Uk Limited | Isoquinoline compounds and methods for treating HIV |
| BR112014006643A2 (pt) * | 2011-09-20 | 2017-04-04 | Hoffmann La Roche | compostos de imidazopiridina, composições e métodos de uso dos mesmos |
| EP2817308B1 (en) * | 2012-02-23 | 2016-09-07 | AbbVie Inc. | Pyridopyrimidinone inhibitors of kinases |
-
2015
- 2015-09-02 BR BR112017003651A patent/BR112017003651A2/pt not_active IP Right Cessation
- 2015-09-02 MX MX2017002544A patent/MX2017002544A/es unknown
- 2015-09-02 WO PCT/EP2015/070082 patent/WO2016034642A1/en not_active Ceased
- 2015-09-02 RU RU2017108909A patent/RU2690853C2/ru not_active IP Right Cessation
- 2015-09-02 EP EP15762963.5A patent/EP3189051A1/en not_active Withdrawn
- 2015-09-02 CN CN201580047253.7A patent/CN106795154B/zh not_active Expired - Fee Related
- 2015-09-02 US US15/507,941 patent/US9944641B2/en not_active Expired - Fee Related
- 2015-09-02 JP JP2017512003A patent/JP2017525734A/ja active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009112524A1 (en) * | 2008-03-12 | 2009-09-17 | 4Sc Ag | Pyridopyrimidines as plk1 ( polo-like kinase) inhibitors |
| JP2015504081A (ja) * | 2012-01-23 | 2015-02-05 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｉｇｆ−１ｒ／ｉｒ阻害剤としての５，８−ジヒドロ−６ｈ−ピラゾロ［３，４−ｈ］キナゾリン |
| JP2016515537A (ja) * | 2013-03-15 | 2016-05-30 | ダナ ファーバー キャンサー インスティテュート，インコーポレイテッド | ピリミド−ジアゼピノン化合物および障害の治療方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| BR112017003651A2 (pt) | 2017-12-05 |
| CN106795154A (zh) | 2017-05-31 |
| US20170240544A1 (en) | 2017-08-24 |
| RU2017108909A (ru) | 2018-10-03 |
| US9944641B2 (en) | 2018-04-17 |
| RU2017108909A3 (enExample) | 2018-12-13 |
| CN106795154B (zh) | 2019-07-05 |
| RU2690853C2 (ru) | 2019-06-06 |
| MX2017002544A (es) | 2017-07-19 |
| EP3189051A1 (en) | 2017-07-12 |
| WO2016034642A1 (en) | 2016-03-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI338684B (en) | Tetrahydroquinoline derivatives and a process for preparing the same | |
| US10662173B2 (en) | Indole and pyrrole compounds, a process for their preparation and pharmaceutical compositions containing them | |
| JP7541538B2 (ja) | 癌を処置するためのｐｒｃ２阻害剤としてのイミダゾ［１，２－ｃ］ピリミジン誘導体 | |
| JP6715357B2 (ja) | イミダゾピリジンアミンフェニル誘導体およびその使用 | |
| CN112566900B (zh) | 免疫调节剂及其组合物和制备方法 | |
| WO2018214867A1 (zh) | N-(氮杂芳基)环内酰胺-1-甲酰胺衍生物及其制备方法和应用 | |
| JP7624404B2 (ja) | Ｐｒｃ２阻害剤としてのナフチリジン誘導体 | |
| CN105968115B (zh) | 喹啉类化合物、其制备方法、中间体、药物组合物和应用 | |
| WO2018214866A9 (zh) | 一种氮杂芳基衍生物、其制备方法和在药学上的应用 | |
| JP2020512399A (ja) | Ｉｄｏを抑制する化合物、その調製方法及びその使用 | |
| WO2019062328A1 (zh) | 苯胺取代的1,2-二氢吡咯并[3,4-c]吡啶/嘧啶-3-酮衍生物及用途 | |
| JP2019533650A (ja) | Ｅｈｍｔ２阻害剤としての置換された融合二環式または三環式複素環化合物 | |
| CN111303147B (zh) | 吡啶酮衍生物、其组合物及作为抗流感病毒药物的应用 | |
| CN104379568A (zh) | 喹唑啉二酮衍生物 | |
| JP2021500334A (ja) | Ｅｈｍｔ２阻害剤としてのアミン置換複素環化合物、その塩、及びそれらの合成方法 | |
| AU2002367323A8 (en) | Benzothieno (3,2- | |
| WO2001064680A1 (en) | Myt1 kinase inhibitors | |
| TW202444700A (zh) | 作為sarm1抑制劑之經取代1h-吡唑-4-甲醯胺化物 | |
| US9944641B2 (en) | Isoquinolinone derivatives useful in the treatment of cancer | |
| TW509692B (en) | 2-amino-7-(1-substituted-2-hydroxyethyl)-3,5-dihydro-pyrrolo[3,2-d]pyrimidin-4-ones | |
| JP2017532299A (ja) | Ｆｔｌ３およびｊａｋの阻害剤としての大環状ｎ−アリール−２−アミノ−４−アリール−ピリミジンポリエーテルの誘導体 | |
| WO2022171088A1 (zh) | 吡唑并[3,4-d]嘧啶-3-酮衍生物 | |
| CN114751899A (zh) | 一种二芳基脲类mTOR激酶抑制剂及其药物组合物和应用 | |
| HK1233639A1 (en) | Isoquinolinone derivatives useful in the treatment of cancer | |
| CN112119065B (zh) | 苯并二氮杂环类化合物、其制备方法及用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180903 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20180903 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190517 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20190516 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20200107 |